Deprescribing proton pump inhibitors: why, when and how

Peter Bytzer
Med J Aust 2018; 209 (10): . || doi: 10.5694/mja18.00674
Published online: 12 November 2018

The focus should primarily be on avoiding unnecessary long term prescribing of PPIs

For more than 25 years, proton pump inhibitors (PPIs) have been the mainstay of therapy for acid-related disorders, particularly peptic ulcer disease and gastro-oesophageal reflux disease (GORD). In recent decades, prescribing of PPIs has increased considerably around the world. According to a recent national drug utilisation study, prescribing of PPIs increased fourfold in Denmark between 2002 and 2014, with the increase particularly marked among older patients; 7% of all adults and 14% of adults over 60 were covered by PPI prescriptions.1 The increased prescribing of PPIs is driven primarily by the accumulation of existing users rather than by new users; inappropriate prescribing and long term use, rather than genuine clinical need for ulcer prophylaxis, appear to underlie the high prevalence of PPI prescribing.2 Changes to public subsidisation of PPI costs and interventions for improving adherence to guidelines and promoting the rational use of PPIs have not had a substantial influence on prescribing patterns.

  • University of Copenhagen, Køge, Denmark


Competing interests:

No relevant disclosures.

  • 1. Pottegård A, Broe A, Hallas J, et al. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therap Adv Gastroenterol 2016; 9: 671-678.
  • 2. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83: 66-68.
  • 3. Vaezi, MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153: 35-48.
  • 4. Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27: 443-454.
  • 5. Lødrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol 2013; 48: 515-522.
  • 6. Haastrup P, Paulsen MS, Begtrup LM, et al. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract 2014; 31: 625-630.
  • 7. Reimer C, Bytzer P. Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse. Eur J Gastroenterol Hepatol 2010; 22: 1182-1188.
  • 8. Murie J, Allen J, Simmonds R, de Wet C. Glad you brought it up: a patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice. Qual Prim Care 2012; 20: 141-148.
  • 9. Björnsson E, Abrahamsson H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24: 945-954.
  • 10. Inadomi, JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121: 1095-1100.
  • 11. National Prescribing Service. Reviewing PPIs for GORD. June 2018. (viewed July 2018).
  • 12. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003; 98(3 Suppl): S31-S39.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.